Powerful Medical’s AI ECG Technology Earns FDA De Novo Authorization for Heart Attack Detection; Werfen Secures US FDA 510(k) Clearance and CE Mark for Aptiva® APS IgA Reagent; Ontario Introduces Fetal Blood Type Screening to Improve Pregnancy Care; Medvue Concorde Acquires Next-Generation AI-Powered MRI System; Cardiol Therapeutics Hits Phase III MAVERIC Enrollment Target Early and Expands Pivotal Trial for CardiolRx; Ferronova Reports Preliminary MAGMAP Results in 62-Patient Gastric and Oesophageal Cancer Trial

Powerful Medical Receives FDA De Novo Authorization for AI-Based ECG Model for Acute Heart Attack Detection 

On 15 September 2026, Powerful Medical announced that the U.S. Food and Drug Administration had granted De Novo authorization for its Queen of Hearts ACS AI ECG Model. The AI-powered technology was developed to analyze ECGs for findings associated with urgent acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI) and STEMI-equivalent conditions, and to alert clinicians when urgent evaluation was required.

The FDA authorization established a new device classification for AI-based ECG models intended to support the identification of acute and potentially life-threatening cardiovascular conditions. The authorization followed the product’s earlier Breakthrough Device Designation in March 2025 and participation in the FDA’s Total Product Life Cycle Advisory Program. Queen of Hearts was developed as part of Powerful Medical’s PMcardio cardiovascular care platform, which used artificial intelligence to analyze ECG data and support clinical decision-making. The platform was designed to integrate ECG interpretation into healthcare workflows spanning pre-hospital care, emergency departments, and cardiology services.

The technology was intended to facilitate earlier identification of patients with suspected acute coronary syndrome and support rapid escalation to cardiology teams. This approach was designed to assist healthcare providers in prioritizing patients who could require urgent cardiology assessment and cardiac catheterization.

The company reported that the technology was supported by more than 20 peer-reviewed studies, including randomized controlled trials involving more than 40,000 patients across four continents. Published research cited by the company reported higher sensitivity than conventional interpretation approaches, fewer false-positive results, and faster treatment pathways. These performance claims were reported by Powerful Medical and should be distinguished from the FDA’s regulatory authorization itself. The company had previously deployed its technology in Europe following CE marking. According to Powerful Medical, the system had been used to identify more than 120,000 heart attacks during 2025 in Europe and had contributed to shorter treatment times in a substantial proportion of those cases.

Following the U.S. authorization, Powerful Medical accelerated plans to deploy PMcardio across U.S. healthcare systems. The platform was intended to provide AI-assisted ECG assessment from the first point of patient contact and facilitate information transfer between emergency and cardiology teams. Overall, the FDA authorization represented a regulatory development for the AI-based cardiac diagnostics market, particularly AI-enabled ECG interpretation for acute coronary syndrome and heart attack detection. It also expanded the regulatory pathway for artificial-intelligence technologies designed to assist clinicians with rapid cardiovascular diagnosis and triage.

“This milestone reflects our mission to ensure every patient has access to fast, accurate heart attack diagnosis, regardless of where they present,” said Martin Herman, CEO and Co-founder of Powerful Medical. “With FDA De Novo authorization in place, we can scale adoption and bring this technology into routine clinical care across the United States.”

As per DelveInsight’s “Cardiovascular Imaging Equipment Market Report,” the cardiovascular imaging equipment market is estimated to grow at a CAGR of 6.71% during the forecast period from 2024 to 2030. The incidence of cardiovascular diseases (CVDs) is rising due to lifestyle changes, smoking, lack of physical activity, excessive alcohol consumption, obesity, and other factors that are escalating the global market of cardiovascular imaging equipment. Additionally, public health campaigns and initiatives aimed at raising awareness about cardiovascular health encourage individuals to undergo regular check-ups and screenings. Increased public knowledge about the importance of early detection and management of heart diseases leads to higher utilization of cardiovascular imaging services. Furthermore, key cardiovascular imaging equipment manufacturers are continuously investing in research and development to introduce innovative cardiovascular imaging technologies; increased partnerships and collaborations, product launches, and approvals ensure that the market remains dynamic and innovative during the forecast period from 2024 to 2030.

Werfen Announced US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent 

On 23 September 2026, Werfen expanded its antiphospholipid syndrome testing portfolio after receiving U.S. FDA 510(k) clearance and CE Mark approval for its Aptiva APS IgA Reagent in September 2026. The regulatory milestones enabled the company to broaden access to APS testing in the United States and Europe and complete its portfolio covering IgA, IgG, and IgM antibody isotypes.

The Aptiva APS IgA Reagent used particle-based multi-analyte technology to provide semi-quantitative measurement of anti-cardiolipin and anti-beta-2 glycoprotein 1 IgA antibodies from human serum. When used with the IgG and IgM assays, the test provided laboratories with a broader antibody profile that could support the evaluation of primary and secondary antiphospholipid syndrome.

The addition of the IgA reagent strengthened the capabilities of the Aptiva automated autoimmune testing platform and expanded its range of autoimmune disease markers. The platform was designed to process multiple analytes from a single patient sample, supporting laboratory efficiency and higher-throughput autoimmune testing.

The regulatory clearances also increased the availability of comprehensive APS antibody testing across major markets and supported the continued adoption of automated and multi-analyte technologies for autoimmune diagnostics.

“Completing the APS isotype panel with the addition of IgA significantly enhances the clinical value of the Aptiva system,” said Anthony Prestigiacomo, Vice President of Research and Development at Werfen. “APS can present with nonspecific or overlapping symptoms, making diagnosis challenging. By offering all three isotypes, clinicians and laboratories can obtain a more comprehensive assessment that supports informed clinical decision-making and improved patient care.”

As per DelveInsight’s “Autoimmune Disease Diagnostics Market Report,” the global autoimmune disease diagnostics market is estimated to grow at a CAGR of 5.53% during the forecast period from 2024 to 2030 to reach USD 6.41 billion by 2030. The demand for diagnosis of autoimmune diseases is primarily being boosted by the increasing number of cases of autoimmune disorders such as Rheumatoid Arthritis, Type I Diabetes, and Addison’s Disease, among others. Additionally, the rising awareness among people regarding early disease diagnosis and the rising technological advancement in the healthcare domain are also contributing to the growth of the Autoimmune Diagnostics Market during the forecast period from 2024 to 2030.

Ontario Launched Fetal Blood Type Screening to Advance Pregnancy Care 

On 23 September 2026, Ontario introduced province-wide fetal blood type screening to support more personalized pregnancy care. BORN Ontario and Prenatal Screening Ontario launched two publicly funded prenatal tests that used a maternal blood sample to determine the fetus’s blood type. The initiative included fetal RHD screening for RhD-negative pregnant individuals and fetal blood group genotyping for pregnancies involving selected antibodies.

The screening program was intended to improve the identification and management of pregnancies at risk of alloimmunization and hemolytic disease of the fetus and newborn. By determining fetal blood type non-invasively, healthcare providers were able to better identify pregnancies requiring Rh immune globulin treatment and closer monitoring, while reducing unnecessary interventions and exposure to blood products.

The initiative formed part of Ontario’s broader investment in prenatal screening services and strengthened the adoption of precision-based approaches in prenatal care. BORN Ontario implemented the program in collaboration with Sinai Health and Canadian Blood Services.

“Our government is ensuring Ontario families have access to innovative and world-class prenatal care. The introduction of non-invasive fetal blood type screening is another step forward in providing expectant parents with the best possible care while strengthening Ontario’s leadership in pregnancy and newborn health.” The Honourable Sylvia Jones, Deputy Premier and Minister of Health

“This new screening program represents a significant advancement in precision prenatal care. By better identifying which pregnancies require intervention and monitoring, we can tailor care more effectively and improve outcomes for both pregnant individuals and babies.” Dr. Barbra de Vrijer, Maternal-Fetal Medicine Specialist 

As per DelveInsight’s “Non-Invasive Prenatal Testing Market Report,” the global non-invasive prenatal testing (NIPT) market was valued at USD 7.2 billion in 2025 and is projected to reach USD 18.94 billion by 2034, driven by rising global maternal age, increasing awareness of chromosomal abnormality risk, rapid advances in next-generation sequencing technologies, and expanding insurance reimbursement coverage across major markets. The global non-invasive prenatal testing market is growing at a CAGR of 11.65% during the forecast period from 2026 to 2034.

Medvue Concorde Acquired Next-Generation MRI System Powered by Artificial Intelligence  

On 23 September 2026, Medvue Concorde acquired a next-generation MRI system equipped with artificial intelligence, becoming the first medical imaging clinic in Quebec to introduce the Siemens MAGNETOM Flow. Elite. The installation strengthened the clinic’s imaging capabilities in Laval by supporting faster examinations, improved patient comfort, and a broader range of specialized MRI services.

The MRI system incorporated AI-based technology to optimize image acquisition and processing while maintaining high-quality imaging. It was designed with a wider opening to improve patient comfort and included integrated sensors that simplified certain aspects of examination preparation. The technology also supported imaging in the presence of natural patient movement, which helped reduce the duration of selected examinations.

The acquisition enabled Medvue Concorde to expand its MRI offering to include advanced cardiac imaging and prostate MRI, alongside musculoskeletal, neurological, abdominopelvic, and thoracic examinations. The system also featured an energy-efficient design that required substantially less helium than conventional MRI systems, supporting a lower-resource approach to medical imaging.

“Artificial intelligence is opening up new possibilities in medical imaging, including allowing us to optimize image acquisition and reconstruction while improving the efficiency of certain exams,” said Dr. Viviane Khoury, MD, FRCPC, musculoskeletal radiologist and Medical Director at Medvue Concorde.

According to DelveInsight’s “Magnetic Resonance Imaging (MRI) Devices Market Report”, the magnetic resonance imaging devices market was valued at USD 8,207.06 million in 2024, growing at a CAGR of 6.54% during the forecast period from 2025 to 2032 to reach USD 13,553.33 million by 2032. The rising prevalence of various chronic disorders, such as cardiovascular diseases, cancer, and neurological conditions, is fueling the demand for precise diagnostic tools like MRI, which offers superior imaging capabilities for soft tissues and organs. Additionally, the increasing awareness and the emphasis on early diagnosis of chronic disease are encouraging patients and healthcare providers to adopt MRI for timely intervention. Furthermore, technological advancements play a crucial role in boosting the MRI market, with innovations such as high-field and open MRI systems, functional MRI (fMRI), and faster scan times improving the accuracy, comfort, and efficiency of the imaging process. Collectively, these factors are expected to expand the demand for magnetic resonance imaging devices globally during the forecast period from 2025 to 2032.

Cardiol Therapeutics Achieved Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy 

On 23 September 2026, Cardiol Therapeutics achieved its initial enrollment target for the Phase III MAVERIC trial ahead of schedule and expanded the study to strengthen the evaluation of CardiolRx in recurrent pericarditis. As of September 23, 2026, the company had enrolled 110 patients, reaching its original recruitment target earlier than anticipated. Following a blinded review that identified fewer pericarditis recurrences than expected, the MAVERIC Steering Committee recommended increasing enrollment to as many as 150 patients.

The MAVERIC trial was designed as a randomized, double-blind, placebo-controlled, multicenter Phase III study assessing whether CardiolRx could reduce the risk of recurrent pericarditis episodes. The expansion was intended to provide a sufficient number of recurrence events to support the planned statistical analysis and strengthen the assessment of the treatment’s efficacy.

The enrollment expansion subsequently shifted the expected timing of topline results to mid-2027, compared with the company’s earlier expectation of the first quarter of 2027. Cardiol Therapeutics stated that its existing capital resources were expected to support completion of the MAVERIC study, with its cash runway extending into the first quarter of 2028.

The development further advanced Cardiol Therapeutics’ clinical program for recurrent pericarditis, following the completion of its Phase II MAVERIC-Pilot study. The U.S. FDA had also granted CardiolRx Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis.

“A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx™ or placebo shows a lower level of pericarditis recurrence than anticipated, an observation we view as encouraging, particularly as we are not aware of changes in routine clinical practice that would explain this finding,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

According to DelveInsight’s ”Anti-Inflammatory Drug Market Report,” The anti-inflammatory drugs market is estimated to advance at a CAGR of 5.73% during the forecast period from 2024 to 2030. The demand for anti-inflammatory drugs is primarily being boosted by the increasing prevalence of various chronic diseases such as asthma, arthritis, chronic obstructive pulmonary disease (COPD), and other diseases. Further, the increasing research on anti-tumor necrosis factor (TNF), interleukins, Janus kinase inhibitors, anti-inflammatory biologics, immune selective anti-inflammatory derivatives (ImSAIDs), the rising prevalence of auto-immune diseases, increasing focus on developing biosimilars, drug launches and approvals across the globe, among others, are contributing to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024 to 2030.

Ferronova Announced Preliminary Results of MAGMAP, a 62-Patient Gastric and Oesophageal Cancer Trial Investigating Lymph Node Mapping

On 16 September 2026, Australian medical technology company Ferronova reported preliminary results from its MAGMAP multicenter clinical trial, which evaluated a nanoparticle-based lymph node mapping technology in patients with gastric and oesophageal cancers. The findings were presented at the 22nd ISDE World Congress for Esophageal Diseases in Kyoto, Japan.

The study assessed FerroTrace®, a surgical oncology marker designed to help clinicians identify lymph nodes draining the primary tumor, including sentinel lymph nodes. The technology was administered to 62 patients, with no toxicity-related adverse events reported during the preliminary assessment.

Among patients considered potentially eligible for a less extensive surgical approach, sentinel lymph nodes were successfully identified in 23 patients, representing a 96% identification rate. No false-negative results were observed among the seven evaluated node-positive patients, while the patient-level negative predictive value of sentinel node pathology reached 100% in 16 assessed patients.

The trial also evaluated patients with gastric-oesophageal junction and distal oesophageal cancers. In the assessed node-positive cases, the lymphatic drainage identified using FerroTrace corresponded with the direction of the positive lymph nodes. The findings also indicated that some patients with Siewert Type I or II cancers had lymphatic drainage toward the gastric lymphatic basin, demonstrating the potential utility of lymphatic mapping in planning less extensive surgery for selected patients.

Overall, 68% of patients had at least one sentinel lymph node identified outside the tissue that would normally be removed during standard-of-care surgery. These preliminary findings indicated that nanoparticle-based lymphatic mapping could support more precise identification of lymphatic involvement and potentially assist surgeons in tailoring the extent of surgical intervention.

Ferronova planned to continue evaluating the technology in a larger patient population to further assess its potential application in individualized surgical management of gastric and oesophageal cancers.

“To our knowledge, this study was the first where a marker was injected before pre-surgical chemotherapy or radiotherapy and shown to persist and be detectable at the time of surgery.  The preliminary results are extremely promising.

“The absence of false-negatives and the high negative predictive value observed in this preliminary cohort of patients with earlier-stage disease are encouraging and suggest the potential to minimise surgery in selected patients. Future research will build on these findings by investigating a larger patient cohort. We hope this ongoing work will identify new opportunities to individually tailor treatment approaches.”

According to DelveInsight’s “Gastric Cancer Diagnostics Market Report,” the gastric cancer diagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The demand for gastric cancer diagnostics is primarily being driven by the rising cases of gastric cancer across the globe. The growing prevalence of GERD and other stomach-related conditions, coupled with increasing cases of stomach infections such as H. Pylori and gastroenteritis, is contributing to the growth of the market. Further, rising obesity and smoking habits leading to the development of stomach cancer are some of the key factors that are driving the market growth of the gastric cancer diagnostics market during the forecast period from 2024 to 2030.